Grace Therapeutics, Inc.
GRCE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $47 | $47 | $31 | $43 |
| - Cash | $17 | $20 | $22 | $11 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $31 | $27 | $9 | $32 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$3 | -$0 | -$4 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$3 | $1 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.06 | -0.21 | 0.046 | -0.36 |
| % Growth | 71.4% | -552.6% | 112.9% | – |
| Operating Cash Flow | -$3 | -$2 | -$3 | -$4 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$2 | -$3 | -$4 |